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Abstract
Background:  Cationic antimicrobial peptides (CAPs) with antitumor activity constitute a
promising group of novel anticancer agents. These peptides induce lysis of cancer cells through
interactions with the plasma membrane. It is not known which cancer cell membrane components
influence their susceptibility to CAPs. We have previously shown that CAPs interact with the two
glycosaminoglycans (GAGs), heparan sulfate (HS) and chondroitin sulfate (CS), which are present
on the surface of most cells. The purpose of this study was to investigate the role of the two GAGs
in the cytotoxic activity of CAPs.
Methods: Various cell lines, expressing different levels of cell surface GAGs, were exposed to
bovine lactoferricin (LfcinB) and the designer peptide, KW5. The cytotoxic effect of the peptides
was investigated by use of the colorimetric MTT viability assay. The cytotoxic effect on wild type
CHO cells, expressing normal amounts of GAGs on the cell surface, and the mutant pgsA-745, that
has no expression of GAGs on the cell surface, was also investigated.
Results:  We show that cells not expressing HS were more susceptible to CAPs than cells
expressing HS at the cell surface. Further, exogenously added heparin inhibited the cytotoxic effect
of the peptides. Chondroitin sulfate had no effect on the cytotoxic activity of KW5 and only minor
effects on LfcinB cytotoxicity.
Conclusion: Our results show for the first time that negatively charged molecules at the surface
of cancer cells inhibit the cytotoxic activity of CAPs. Our results indicate that HS at the surface of
cancer cells sequesters CAPs away from the phospholipid bilayer and thereby impede their ability
to induce cytolysis.
Background
Cationic antimicrobial peptides (CAPs), also termed host
defense peptides, play a part in the innate immune system
[1]. CAPs can be assigned into two broad groups based on
their target specificity, one group comprising antimicro-
bial activity, such as defensins [2,3], and cecropins [4],
which have specificity for prokaryotic cell membranes,
and a second group, the venom peptides with activity
against both prokaryotic and eukaryotic cell membranes
e.g. melittin [5] and mastoparan [6]. In addition, some of
the CAPs show selective activity against cancer cells. These
peptides act via a non-receptor-mediated pathway and
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constitute a promising group of novel anticancer agents
with a new mode of action and a broad spectrum of anti-
cancer activity. Several studies, included our earlier
reported in vivo studies, indicate that CAPs may have a
potential for local treatment of solid tumors [7-10]. Com-
pared to conventional chemotherapy these CAPs display a
higher specificity for cancer cells versus normal cells
[11,12]. In addition, the peptides are able to kill cancer
cells that have become resistant to conventional chemo-
therapeutics [13-16]. It has also been reported that certain
CAPs have the potential to enhance the cytotoxic activity
of different chemotherapeutics against multi-drug resist-
ant tumor cells [13-15]. The reason why CAPs display
activity against chemoresistant cancer cells probably lies
in their rapid mode of action against the plasma mem-
brane, resulting in lysis of the cells [17]. Most of the CAPs
selective for cancer cells interact with the target membrane
through the "carpet model", where the peptides align par-
allel to the outer membrane surface and permeate the
membrane after a threshold concentration of peptides
have been reached [18,19]. In addition, some CAPs can
also trigger apoptosis in cancer cells via mitochondrial
membrane disruption [20].
It is not yet clarified which components in the plasma
membrane render cancer cells more susceptible to CAPs
than non-malignant cells. Due to the cationic nature of
the peptides, the interaction with the cell surface of the
target cells is most likely facilitated by negatively charged
molecules in the plasma membrane. Whereas the plasma
membranes of non-malignant eukaryotic cells consist pri-
marily of zwitterionic and neutral phospholipids [21], a
number of studies have revealed that the outer membrane
leaflet of cancer cells is more negatively charged than their
normal counterparts. An elevated expression of the ani-
onic phospholipid phosphatidylserine in the outer leaflet
of the plasma membrane has been found in several types
of cancer cell lines [22-25]. Alterations in the carbohy-
drate portion of glycoproteins and glycolipids, including
increased sialylation, also contributes to a more nega-
tively charged tumor cell surface [26]. The enhanced
expression of terminal sialic acids on cell surface N-linked
glycans and O-linked glycans has been reported as a char-
acteristic in a variety of cancers [27].
Proteoglycans (PGs) are also expressed on the cell surface.
These are characterized by highly negatively charged gly-
cosaminoglycan (GAG) side chains attached to a core pro-
tein [28]. Two major classes of GAG side chains are
heparan sulfate (HS) and chondroitin sulfate (CS). These
molecules consist of a linear repeat of up to 100 disaccha-
ride units [29,30]. Both HS and CS are highly sulfated
with an average number of approximately 1.2 and 1.0
negatively charged sulfate groups per disaccharide unit,
respectively [31,32]. The sulfate groups make therefore
the PGs some of the most anionic molecules on the cell
surface. It has been shown that several cancer cells have a
different expression of cell surface PGs, compared to their
normal counterpart cells [33-35]. In addition, it has been
shown that the degree and pattern of sulfation of the GAG
chains may be altered during malignant transformation
[36,37].
One member of the CAP family is bovine lactoferricin
(LfcinB). This peptide displays cytotoxic activity against a
variety of cancer cells in vitro, without harming normal
cells [8,38]. In addition, LfcinB is able to prevent tumor
growth and metastasis in several mouse models [7,8,39]).
Previous studies have revealed that LfcinB induces cell
death in tumor cells by targeting the plasma membrane
and after internalization, the mitochondria [8].
We have previously shown that LfcinB binds to GAGs
[40]. Since the fundamental activity of antimicrobial pep-
tides stems from their ability to interact with negatively
charged membrane molecules, we hypothesized that
GAGs at the surface of target cells may interact with CAPs
and enhance their cytotoxic activity. In the present study
the role of GAGs in the cytotoxic activity of LfcinB was
thus investigated. LfcinB is a 25-mer peptide with a
disulfide bridge that forms a stabilized amphipatic β-sheet
structure. In addition, the KW5 peptide, a 21-mer peptide
designed to adopt an idealized amphipathic α-helix was
also included in the study.
Methods
Reagents
The LfcinB peptide was provided by the Centre for Food
Technology (Queensland, Australia). All Fmoc-amino
acids, Fmoc-resins and chemicals used during peptide
synthesis, cleavage and precipitation were purchased from
PerSeptive (Hertford, UK), Fluka (Buchs, Switzerland)
and Sigma-Aldrich (St. Louis, MO). Fetal bovine serum
(FBS) was obtained from Biochrom KG (Berlin, Ger-
many), and L-glutamine from Gibco (Paisley, Scotland).
MTT (3-(4, 5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazo-
lium bromide) was obtained from Sigma-Aldrich (Oslo,
Norway). Heparitinase (EC 4.2.2.8) and chondroitinase
ABC (EC 4.2.2.4) were from Seikagaku Corporation
(Chuo-ku, Tokyo, Japan). Heparin (H-3393) and chon-
droitin sulfate (C-4384) were obtained from Sigma-
Aldrich (Oslo, Norway). [35S]Sulfate (code SJS-1) was pur-
chased from Amersham Biosciences (Buckinghamshire,
England).
The lymphoma cell lines KMS-5, KMM-1 and Sudhl-4
were a kind gift from Mark Raffeld, Hematophathology
Section, Laboratory of Pathology, National Cancer Insti-
tute, National Institutes of Health, Bethesda, MD. The
lymphoma cell lines Raji and Ramos were provided by Dr.BMC Cancer 2009, 9:183 http://www.biomedcentral.com/1471-2407/9/183
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Michael Norcross, Division of Hematologic Products,
Center for Biologics Evaluation and Research, Food and
Drug Administration, Bethesda, MD, while the lym-
phoma cell line U-266, colon carcinoma cell line HT-29
and the melanoma cell line FEMX were purchased from
ATCC. Jeffery D. Esko, Department of Cellular and Molec-
ular Medicine, University of California, San Diego, USA,
kindly provided us with the mutant Chinese hamster
ovary cell line pgsA-745, which does not express GAGs at
the cell surface, as well as the wild type CHO-K1 that
expresses normal amounts of GAGs [41,42].
Peptide synthesis, purification and analysis
The peptide KW5, ((KAAKKAA)3 W 7,9,16), was synthe-
sized by solid-phase methods using standard Fmoc chem-
istry on a Pioneer Peptide synthesizer (Applied
Biosystems, Foster City, CA). Crude peptides were puri-
fied by preparative RP-HPLC (Waters, Milford, MA) using
a C18 column (Delta-Pak™ C18, 100 Å, 15 μm, 25–100
mm), and analyzed on an analytical C18 HPLC column
(Delta-Pak™ C18, 100 Å, 5 μm, 3.9 × 150 mm) (Waters,
Milford, MA). The purity of the peptides was found to be
> 95%. Peptide characterization was done by positive ion
electrospray ionization mass spectrometry on a VG quat-
tro quadrupole mass spectrometer (VG Instruments Inc.,
Altringham, UK).
Cell cultures
The HT-29 and FEMX cell lines were maintained as mon-
olayer cultures in RPMI-1640 supplemented with 10% (v/
v) FBS and 1% L-glutamine, while the CHO-K1 and pgsA-
745 cell lines were cultured in HAM's-F12 supplemented
with 10% (v/v) FBS and 1% L-glutamine. All the lym-
phoma cell lines were grown in suspension in RPMI-1640
medium supplemented with 10% (v/v) FBS and 1% L-
glutamine. All cells were grown in tissue culture flasks in
humidified atmosphere of 95% air and 5% CO2 at 37°C.
Cytotoxicity assay
The colorimetric MTT viability assay was used to investi-
gate the cytotoxic effect of the peptides. The FEMX and
HT-29 cells were seeded at a concentration of 2 × 105 cell/
ml, and the CHO-K1 and pgsA-745 cells at a concentra-
tion of 1.5 × 105 cell/ml in a volume of 0.1 ml in 96-well
plates. The cells were allowed to adhere overnight in com-
plete medium. Before adding different concentrations of
the peptides (1–500 μg/ml) to the cells, the culture
medium was removed and the cells were washed twice in
serum-free culture medium. The non-adherent lym-
phoma cell lines were seeded at a density of 4 × 105 cells/
ml using serum-free medium. The cells were incubated
with the LfcinB peptide at 37°C for 24 h or with the KW5
peptide for 30 min. Due to our previous structure-activity
relationship studies on lactoferrrin and LfcinB [7,43]
structural parameters important for lytic activity against
cancer cells are optimized in de novo designed peptides.
Hence, the KW5 peptide is more active and kills cancer
cells more efficiently than LfcinB. Cells in serum-free
medium alone were used as a negative control whereas
cells treated with 1% Triton X-100 in serum-free medium
were used as a positive control for 100% cell death. After
incubation, 10 μl (adherent cells) or 20 μl (non-adherent
cells) MTT-solution (5 mg MTT per ml phosphate buff-
ered saline) was added to each well and the incubation
was continued for 2 h. A volume of 80 μl or 130 μl per
well was removed from the non-adherent and the adher-
ent cells, respectively. In order to dissolve the formazan
crystals, 100 μl of 0.04 M HCl in isopropanol was added
and the plates were shaken for 1 h on a Thermolyne Roto
Mix (Dubuque, IA) at room temperature. The optical den-
sity was measured on a microtitre plate reader (Ther-
momax Molecular Devises, NJ). Cell survival was
determined from the ΔA590 nm relative to the negative
control (100% living cells) and expressed as 50% inhibi-
tory concentration (IC50).
Sodium chlorate treatment
The FEMX and HT-29 cells were seeded at a concentration
of 2 × 105 cell/ml in a volume of 0.1 ml in 96-well plates.
The cells were incubated for 24 h at 37°C in complete
medium supplemented with 30 mM sodium chlorate,
which decreases sulfation by inhibiting ATP-sulphurylase
[44]. After the treatment period the culture medium con-
taining sodium chlorate was removed and the cells were
washed with serum free RMPI-1640 medium before the
cytotoxic activity of the peptides were investigated using
the MTT assay described above.
Heparitinase treatment
Heparitinase purified from Flavobacterium heparinum was
used for enzymatic cleavage of cell surface HS. Hepariti-
nase (0.1 U) was dissolved in 100 μl 0.1% M Tris acetate
(pH 7.3). FEMX and HT-29 cells were seeded at a concen-
tration of 1 × 105 cell/ml in a volume of 0.1 ml in 96-well
plates. After 48 h at 37°C the cells were treated with 0, 01
U heparitinase in serum free medium for 2 h at 37°C.
Thereafter some cell cultures were washed with serum free
medium before the cytotoxic activity of the peptides was
investigated. In other cell cultures heparitinase was
present during the whole peptide incubation period.
Radiolabeling and isolation of 35S-labeled macromolecules
Cell cultures were radiolabeled for 20 h by adding
[35S]sulfate to a final concentration of 50 μCi/ml at the
time of cell plating. To be able to compare the amount of
35S-labeled macromolecules synthesized by the different
cell lines, the cells were cultured at same level of sub-con-
fluence. After the incubation time, the plasma membrane-
associated 35S-labeled macromolecules were harvested by
washing the cells twice with serum free-medium and sub-BMC Cancer 2009, 9:183 http://www.biomedcentral.com/1471-2407/9/183
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sequently incubated for 15 min at 37°C in the presence of
10 μg/ml of trypsin [45]. Free [35S]sulfate was removed by
gel filtration on Sephadex G50 Fine columns (bed volume
4 ml, equilibrated with 0.5 M Tris/HCl, pH 8.0 and 0.15
M NaCl and eluted with dH2O). Aliquots from the mem-
brane fractions were analyzed for radioactivity in a scintil-
lation counter after the addition of Ultima Gold XR
scintillation fluid. The rest of the material was immedi-
ately frozen and stored until further analysis.
Alkali treatment and gel chromatography
The 35S-labeled macromolecules were subjected to alkali
treatment (0.5 M NaOH over night at 45°C, followed by
neutralization with 0.5 M HCl), resulting in liberation of
free 35S-labeled GAG chains. The 35S-labeled macromole-
cules were subjected to Superose 6 gel chromatography
both before and after alkali treatment. Markers for void
(Vo) and total volume (Vt) were blue dextran and [35S]sul-
fate, respectively. The columns were run in 4 M guanidine-
HCl with 0.05 M sodium acetate, pH 5.8. Fractions were
collected and the radioactivity counted in a scintillation
counter.
Selective PG degradation
The 35S-labeled macromolecules were subjected to enzy-
matic treatment with chondroitinase ABC (cABC), which
depolymerizes CS. Incubations with cABC were per-
formed at 37°C overnight with 0.01 U enzyme per sample
in 0.05 M Tris/HCl, 0.05 M sodium acetate, pH 8.0. The
samples were analyzed on Sephadex G-50 Fine columns
(bed volume 4 ml, equilibrated and eluted with the Tris/
HCl buffer). In addition, parallel samples were subjected
to HNO2 treatment at pH 1.5, in order to degrade the HS
chains [46]. The samples were analyzed by Sephadex G-50
Fine columns (bed volume 4 ml, equilibrated and eluted
with dH2O). Aliquots from the collected fractions where
analyzed for radioactivity in a scintillation counter after
the addition of Ultima Gold XR scintillation fluid.
Results
Cytotoxic effect of the peptides
The LfcinB and KW5 peptides were tested for cytotoxic
activity against the melanoma cell line FEMX and the
colon carcinoma cell line HT-29. The cytotoxic activity of
the peptides was determined by the colorimetric MTT via-
bility assay. Dose-response studies revealed that the pep-
tides displayed a significantly higher cytotoxic activity
against the FEMX cells compared to the HT-29 cells (Fig-
ure 1). LfcinB showed a 3.7 fold higher activity against the
FEMX cells (IC50 = 40 μM) compared to the HT-29 cells
(IC50 = 148 μM). The KW5 peptide displayed a 1.8 fold
higher activity against the FEMX cells (IC50 = 30) com-
pared to the HT-29 cells with an IC50 value of 55 μM
(Table 1).
Sodium Chlorate treatment of the target cells enhances 
the cytotoxic effect of the peptides
In order to investigate the role of cell surface PGs for the
cytotoxic effect of the peptides, the cells were incubated
with sodium chlorate, an agent known to decrease the sul-
fation of the GAG chains [47]. The cells were incubated
with sodium chlorate for 24 hours before the different
peptides were added. The cytotoxic activity of the peptides
against chlorate-treated and non-treated cells was investi-
gated (Figure 2). Surprisingly, the results showed that the
peptides displayed a significantly higher effect against the
chlorate-treated cells compared to the non-treated cells,
indicating that negatively charged GAGs at the cell surface
have an inhibitory effect on the cytotoxic activity of the
peptides. Incubating the cells with chlorate under the cho-
The cytotoxic activity of LfcinB and KW5 against FEMX melanoma and HT-29 colon carcinoma cells Figure 1
The cytotoxic activity of LfcinB and KW5 against FEMX melanoma and HT-29 colon carcinoma cells. The dose 
response curves for LfcinB (A) and KW5 (B) are plotted as percent survival of the cells against different peptide concentrations 
(μg/ml). The curves correspond to five experiments performed in duplicate ± SEM.
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sen conditions did not cause any reduction in cell viabil-
ity, as measured by MTT assay (not shown).
GAG deficient CHO cells were more susceptible for the 
peptides
In order to verify the finding that GAGs have an inhibitory
effect on the activity of the peptides, the cytotoxic effect of
LfcinB and KW5 against wild type CHO cells expressing
normal amounts of GAGs on the cell surface, and the
complete null mutant pgsA-745 that has no expression of
GAGs on the cell surface, was investigated [41]. LfcinB dis-
played a significantly higher activity against the GAG defi-
cient pgsA-745 cell line compared to the wild type CHO
cells, with IC50 values of approximately 74 μM and 112
μM, respectively (Figure 3A). KW5 also displayed a much
higher activity against the GAG deficient pgsA-745 cell
line compared to the wild type cells, with IC50 values of 32
μM and 170 μM, respectively (Figure 3B). These results
confirm that GAGs expressed by the target cells inhibit the
activity of the peptides.
Determination of the type of GAGs at the cell surface
In order to compare the amount of GAGs expressed on the
cell surface of FEMX and HT-29 the cells were metaboli-
cally labeled with [35S]sulfate. After removal of the culture
medium, the GAGs associated with the plasma membrane
were harvested as described in "Methods". The amount of
35S-labeled macromolecules in the membrane fraction
was quantified after Sephadex G-50 chromatography, as
previously described [48]. The 35S-labeled macromole-
cules were almost exclusively GAGs. The membrane frac-
tion of the FEMX cells contained a higher amount (~45%)
of 35S-labeled GAGs compared to the HT-29 cells (Figure
4). Cell surface PGs can be substituted with both CS and
HS chains [49]. Previously, we have reported that LfcinB
Table 1: The cytotoxic effect of LfcinB and KW5 against FEMX 
and HT-29 cells.
Peptides FEMX
aIC50 (μM)
HT-29
IC50 (μM)
Ratio(IC50)HT-29 cells/FEMX cells
LfcinB 40 ± 7 148 ± 8 3.7
KW5 30 ± 3 55 ± 14 1.8
aIC50 is the inhibitory concentration of the peptides where 50% of the 
cells are killed.
Data are mean ± SEM (n = 5).
The cytotoxic effect of LfcinB and KW5 against sodium chlorate treated and non-treated FEMX and HT-29 cells Figure 2
The cytotoxic effect of LfcinB and KW5 against sodium chlorate treated and non-treated FEMX and HT-29 
cells. The results are shown as the mean IC50 value ± SEM of LfcinB (A) and KW5 (B) against sodium chlorate treated (dotted 
bars) and non-treated (open bars) Femx and HT-29 cells. The experiment was repeated four times in duplicate. Statistics were 
performed by a paired t-test (GraphPad). P values are shown as follows: * P < 0.05 and *** P < 0.001.
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binds with higher affinity to HS than to CS [40]. The
amount of HS and CS at the surface of FEMX and HT-29
cells was therefore investigated by treating the 35S-labeled
macromolecules in the membrane fraction with cABC and
HNO2. About 70% of the 35S-labeled macromolecules in
the membrane fraction of the HT-29 cells were sensitive to
HNO2 treatment, while about 10% were sensitive to cABC
treatment. Hence, it can be concluded that about 70% and
10% of the 35S-labeled macromolecules at the surface of
these cells are HS and CS, respectively. In the membrane
fraction of the FEMX cells about 55% of the 35S-labeled
material could be degraded by cABC, while about 45%
could be degraded by HNO2-treatment (Figure 5). As can
be seen from Figure 5, the HT-29 cells expressed more HS
on the cell surface compared to the FEMX cells, although
the FEMX cells expressed more GAGs in total (HS and CS).
Exogenous heparin inhibited the effect of the peptides
The peptides displayed a lower cytotoxic activity against
the HT-29 cells, which have HS as their major GAG com-
ponent, compared to the FEMX cells, which have CS as
their major GAG component. This, combined with the
fact that the peptides bind more strongly to HS than CS
[40], suggests that it is the HS component of the cell sur-
face PGs that inhibits the cytotoxic effect of the peptides.
To further investigate if the inhibitory effect was due to HS
or CS, the peptides were added to cell cultures together
The cytotoxic effect of LfcinB and KW5 against CHO-K1 and pgsA-745 cells Figure 3
The cytotoxic effect of LfcinB and KW5 against CHO-K1 and pgsA-745 cells. The results are shown as the mean 
IC50 value ± SEM of LfcinB (A) and KW5 (B) against CHO-K1 and pgsA-745. The experiment was performed three times in 
duplicate. Statistics were performed by an unpaired t-test (GraphPad). P values are shown as follows: *** P < 0.001.
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Determination of the amount of [35S]sulfate incorporated  into macromolecules at the cell surface of FEMX and HT-29  cells Figure 4
Determination of the amount of [35S]sulfate incorpo-
rated into macromolecules at the cell surface of 
FEMX and HT-29 cells. Data are shown as mean value ± 
SEM from three independent experiments performed in trip-
licate. Statistics were performed by an unpaired t-test 
(GraphPad). P value is shown as follows: ** P < 0.01.
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with exogenous heparin and CS. At a concentration of 10
μg/ml, heparin and CS displayed the same inhibitory
effect on the cytotoxic activity of LfcinB against the FEMX
cells. However at a concentration of 100 μg/ml, heparin
showed a higher inhibitory effect compared to CS (Figure
6A). The higher ability of heparin to inhibit the cytotoxic
effect of LfcinB compared to CS was further demonstrated
against the HT-29 cells (Figure 6B). Heparin also more
efficiently inhibited the cytotoxic effect of KW5, compared
to CS (Figure 6C–D). These results clearly indicate that the
inhibitory effect of cell surface GAGs is due to HS, and not
to CS.
Lymphoma cells expressing HS at the cell surface were less 
susceptible to the cationic peptides
To further investigate the role of HS in the cytotoxic activ-
ity of the peptides, the FEMX and the HT-29 cells were
treated with heparitinase, an enzyme known to depolym-
erize HS, before addition of the peptides. However, the
results from these experiments were inconsistent, proba-
bly due to technical problems with the enzyme. An indi-
rect approach was therefore chosen. In these experiments
the cytotoxic activity of LfcinB was studied on six different
lymphoma cell lines. Three of the cell lines (KMS-5, U-
266, KMM-1) expressed HS at the cell surface, whereas the
other three (Sudhl-4, Raji, Ramos) did not, as determined
by flow cytometry using an anti-HS antibody, and as
reported elsewhere (Uhlin-Hansen, L. Manuscript in prep-
aration). The LfcinB peptide displayed a significantly
higher cytotoxic activity against the HS deficient cell lines
compared with the HS expressing cell lines (Table 2). The
mean IC50 values obtained against the HS deficient cell
lines and the HS expressing cell line was 13 μM ± 2 and 50
μM ± 6, respectively (P value 0.004) This experiment fur-
ther supports the finding that HS at the cell surface inhib-
its the cytotoxic activity of the peptides.
HT-29 cells synthesize larger PGs than FEMX cells
In addition to the type of GAGs, other features such as the
size of the GAG chains might affect the cytotoxic effect of
the peptides. The size of the proteoglycan molecules and
their GAG chains was therefore analyzed by Superose-6
gel chromatography. The 35S-labeled macromolecules
from the membrane fraction of the FEMX cells and the
HT-29 cells eluted with peak kav values of 0, 33 and 0, 25,
respectively (Figure 7A). This shows that the HT-29 cells
expressed larger proteoglycan molecules at the cell sur-
face, compared to the FEMX cells. Chromatography of
corresponding 35S-labeled material after alkali treatment
revealed a shift in the elution of the peak fractions (Figure
7B), confirming that the GAGs in the membrane fractions
were part of PG molecules. The size of the attached 35S-
labeled GAG chains from the HT-29 and FEMX cells was
almost identical, eluting with peak kav-values of 0,38 and
0,40 respectively. These kav-values correspond to molecu-
lar weight of approximately 48 kDa and 45 kDa. These
results indicate that the larger size of the PGs in HT-29
cells, compared to the FEMX cells, is due to more GAG
chains attached to each core protein, or larger core pro-
teins.
Discussion
It is known that a variety of lytic peptides show a selective
cytotoxic activity against tumor cells compared to normal
cells. It is believed that this selectivity is due to a more neg-
atively charged cell surface of the tumor cells, but the exact
mechanism is not known. The plasma membrane of
almost all mammalian cells contains PGs substituted with
GAG chains. The GAGs are highly anionic due to a large
number of negatively charged sulfate groups [28]. We
have previously shown that LfcinB and other lytic pep-
tides bind to GAGs [27] and we therefore hypothesized
that cell surface GAGs increase binding and therefore in
accordance with work on other anionic membrane com-
ponents increase the cytotoxic activity of CAPs. However,
the present study showed that cell surface GAGs inhibited
the cytotoxic effect of LfcinB and the designer lytic pep-
tide, KW5.
In the initial experiments we used two cell lines which
express different amounts of GAGs at the cell surface; the
melanoma cell line FEMX and the colon carcinoma cell
line HT-29. Both peptides displayed higher cytotoxic
activity against the FEMX cells, which express a larger
amount of GAGs compared to the HT-29 cells. This result
is in agreement with previous studies showing that an
increased negative charge on the cell surface of target cells
Determination of the amount of [35S]sulfate incorporated  into macromolecules at the cell surface of FEMX and HT-29  cells Figure 5
Determination of the amount of [35S]sulfate incorpo-
rated into macromolecules at the cell surface of 
FEMX and HT-29 cells. The experiment was performed 
twice in duplicate with almost identical results.
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enhances the cytotoxic activity of lytic peptides [50,51].
To confirm our hypothesis that it is the negatively charged
sulfate groups on the GAG chains that mediate the bind-
ing of the peptides, the sulfation of the GAGs was reduced
by adding sodium chlorate to the culture medium before
the cells were exposed to the peptides. Chlorate reduces
the overall sulfation of GAGs by competing with sulfate
ions for binding to ATP-sulfyrolase [52]. Interestingly, we
found that the peptides displayed a significantly greater
cytotoxic activity against chlorate-treated cells compared
to non-treated cells, indicating that the negatively charged
GAGs at the cell surface actually reduce the cytotoxic activ-
ity of the peptides. Previous studies have shown that incu-
bating cells with sodium chlorate only leads to a partial
reduction of the sulfation of the GAG chains [53]. This
may explain why the effect of chlorate on the cytotoxic
effect was only moderate.
In order to investigate the involvement of GAGs more
directly, the cytotoxic activity of the peptides was studied
with wild type and GAG-defective CHO cells [41]. These
cells have been widely used to study the role of cell surface
GAGs in various processes such as viral infection, growth
factor signaling and cell adhesion [54]. The pgsA-745 cells
have defective xylosyltransferase, an enzyme necessary for
biosynthesis of HS and CS [41]. The higher cytotoxic activ-
The cytotoxic effect of LfcinB and KW5 against FEMX and HT-29 cells, in the presence of soluble heparin and chondroitin sul- fate Figure 6
The cytotoxic effect of LfcinB and KW5 against FEMX and HT-29 cells, in the presence of soluble heparin and 
chondroitin sulfate. The results are shown as the mean IC50 value ± SEM (n = 5) of LfcinB and KW5 against FEMX (A) and 
HT-29 (B) cells, in the presence of soluble heparin and chondroitin sulfate. The IC50 values obtained from cell cultures contain-
ing 10 μg/ml soluble heparin were compared with cell cultures containing 10 μg/ml soluble CS by an unpaired t-test (Graph-
Pad). The same comparison was performed between cell cultures containing 100 μg/ml soluble heparin and 100 μg/ml soluble 
CS. P values are shown as follows: ** P < 0.01 and *** P < 0.001.
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ity of the peptides against the GAG deficient pgsA-745
cells compared to the wild type CHO cells expressing nor-
mal levels of GAGs at the cell surface clearly indicate that
GAGs have an inhibitory effect on the cytotoxic activity of
these peptides. This finding is in contrast to reports about
other anionic cell surface molecules which have been
shown to enhance the anticancer activity of CAPs [50,51].
Cell surface PGs may be substituted with different types of
GAG chains, either HS or CS [28]. We have previously
shown that LfcinB and other lytic peptides bind with
higher affinity to HS than CS [40]. We therefore examined
the expression pattern of GAGs on the FEMX and HT-29
cells. We found that the FEMX cells expressed cell surface
PGs mostly substituted with CS, whereas the PGs at the
surface of HT-29 cells were mostly substituted with HS.
This expression profile is consistent with previous reports
showing that malignant melanoma cells have a high
expression of CSPGs [55], while the HT-29 cells has a high
expression of HSPGs. [56]. The lower cytotoxic activity of
the peptides against the HT-29 cells compared to the
FEMX cells therefore suggests that the inhibitory effect of
GAGs is attributed to HS and not CS. The addition of sol-
uble heparin and CS to cell cultures is widely used to study
the interaction between various molecules and cell surface
HS and CS [57,58]. In the present study we found that
exogenously added heparin had a stronger inhibitory
effect on the cytotoxic activity of the peptides, compared
to CS. This experiment strongly supports the finding that
it is HS, and not CS, that inhibits the cytotoxic activity of
the peptides. The inhibitory effect of HS was further sup-
ported by the fact that lymphoma cells lacking HS at the
cell surface were much more sensitive to LfcinB than lym-
phoma cells expressing cell surface HS.
Cell surface PGs belong to two different families, the syn-
decans and the glypicans [59,60]. They can be substituted
with both HS and CS side chains, but HS is the dominant
type of GAG on the surface of most cell types [61]. The
complex polysaccharide structure gives HS a higher con-
formational flexibility compared to CS [62]. This may
explain the fact that LfcinB and other lytic peptides bind
with higher affinity to HS than to CS since the sequence
and structural diversity in the lytic peptides may require a
high flexibility in the molecules they bind to. Previous
studies have shown that the antibacterial activity of the
peptides LL-37 [63,64] and α-defensin [65] are inacti-
vated by GAGs. It has also been demonstrated that the
LfcinB peptide and a set of short α-helical peptides are
able to block HSV infection by binding to cell surface HS,
which is used as a target molecule for HSV internalization
Table 2: The cytotoxic effect of LfcinB against lymphoma cell 
lines expressing different levels of HS.
Cell line aCell surface HS bIC50(μM)
KMS-5 + 38
U-266 + 55
KMM-1 + 57
Sudhl-4 - 16
Raji - 13
Ramos - 10
aCell surface HS was measured using an anti-HS antibody and flow 
cytometry. Cell lines marked with + express HS, while cell lines 
marked with -lack HS.
bIC50 is the inhibitory concentration of the LfcinB peptide in (μM) 
where 50% of the cells are killed.
Superose 6 gel chromatography of 35S-labeled macromolecules from the plasma membrane fraction before and after alkali  treatment Figure 7
Superose 6 gel chromatography of 35S-labeled macromolecules from the plasma membrane fraction before 
and after alkali treatment. A) Intact 35S-labeled PGs and B) 35S-labeled GAGs, obtained by alkali treatment. The experi-
ment was performed twice with similar results.
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[40,66,67]. It is believed that PGs with their unbranched
GAG chains extend like a brush out from the surface of the
cells, as shown in the cartoon in Figure 8. As discussed,
our results show that HS at the surface of the target cells
inhibit the cytotoxic activity of the peptides. We therefore
propose that the long, unbranched HS chains can seques-
ter the lytic peptides away from the phospholipid bilayer
and thereby impede their ability to induce cytolysis of the
target cells, as shown in Figure 8.
An earlier finding showing that low-molecular heparin is
less efficient in binding lactoferrin than normal sized
heparin [68], indicates that the size of the GAG chains
could be an important factor for the interaction with the
peptides. In the present study we found the size of the PGs
on the surface of the HT-29 cells to be larger than the PGs
on the surface of the FEMX cells. Larger PGs may keep the
lytic peptides at a longer distance from the phospholipid
bilayer than smaller PGs. The size of the cell surface PGs
may therefore influence the sensitivity of the cells for lytic
peptides. In addition to the size of the proteoglycans the
degree and pattern of sulfation of the GAG chains may
also influence the level of interaction between the pep-
tides and the GAG chains. If the peptides have high
sequence specificity and requires a particular sulfation
pattern in order to interact with the GAGs this would also
affect their binding capacity as shown for growth factors
[69,70], antithrombin III [71] and matrix ligand [72].
It has been shown that phosphatidylserine [51] and sialic
acid [50] found on the cell surface of tumor cells enhance
the antitumor activity of CAPs. Phosphatidylserine is
present at the outer leaflet of many cancer cell lines and a
higher number of sialic acids is present on glycoproteins
and glycolipids on cancer cells compared to normal cells.
Thus, these smaller anionic molecules located closer to
the phospholipid bilayer of the tumor cells might facili-
tate the activity of the peptides whereas the large PGs have
an opposite effect.
Many studies have shown that poorly differentiated
tumors have reduced expression levels of cell surface
HSPGs [35], indicating that the biosynthesis of HS PGs is
reduced in these tumors. The best studied cell surface pro-
teoglycan is syndecan-1. In a wide range of carcinomas it
has been shown that a low expression of syndecan-1 on
tumor cell surfaces correlates with increasing metastatic
potential and poor prognosis [73-75]. In addition to
reduced synthesis, an increased degradation of cell surface
HS may take place. Heparanase is a HS degrading enzyme
released by several cell types [76]. It has been found that
many tumors overexpress heparanase [77]. Further,
increased expression of heparanase is correlated with the
high metastatic capacity of tumor cells [77]. Heparanase
released by the tumor cells degrades HS both in the extra-
cellular matrix and at the cell surface. Hence, the low level
of cell surface HS found in many tumors can be a result of
Schematic model of the interaction of HS chains with CAPs on the cell surface Figure 8
Schematic model of the interaction of HS chains with CAPs on the cell surface.BMC Cancer 2009, 9:183 http://www.biomedcentral.com/1471-2407/9/183
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increased level of heparanase. Alterations in the expres-
sion pattern of HS at the surface of tumor cells, due to
reduced biosynthesis of HS and/or increased expression of
heparanase, can explain, at least partly, the fact that many
cancer cells show increased susceptibility toward certain
CAPs.
Conclusion
In the present study we show for the first time that nega-
tively charged molecules on the surface of tumor cells can
inhibit the antitumor activity of CAPs. Further studies
should be done with other structurally different CAPs to
conclude whether this is the case for all types of CAPs. We
show that the cytotoxic activity was significantly reduced
in cells expressing HS at the surface. Our results indicate
that HS at the surface of cancer cells can sequester the
CAPs away from the phospholipid bilayer and thereby
hinder their ability to induce cytolysis. Previous studies
have shown that low level of cell surface HS is correlated
with high metastatic potential of cancer cells. Our results
indicate that poorly differentiated tumors, with low
expression of cell surface HS, are more susceptible to treat-
ment with CAPs. To confirm this, the effect of CAPs on
tumors with high and low HS expression should be
explored with in vivo studies.
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